|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
3
Treatment Goals in Retinal Vascular Diseases
4
The Residency Report: Cardiovascular risk scores as a window into ocular disease
5

















